Global Intensity Modulated Radiotherapy Market 2023-2030

Global Intensity Modulated Radiotherapy Market 2023-2030

Global Intensity Modulated Radiotherapy Market Size, Share & Trends Analysis Report by Radiation Type (Photon Radiation, Electron Beam Radiation, Proton Radiation, and Carbon ion Radiation), by Application (Prostate Cancer, Breast Cancer, Lung Cancer, Gastrointestinal Cancer, and Other Cancer), and by End Users (Hospitals and Specialty Center), Forecast Period (2023-2030)

Global intensity modulated radiotherapy market is anticipated to grow at a CAGR of 8.7% during the forecast period (2023-2030). Intensity modulated radiation therapy uses advanced computer programs to calculate and deliver radiation directly to the cancer cells from different angles. Treatment modalities comprise radiation therapy, surgery, chemotherapy, immunotherapy, and hormonal therapy. Radiation therapy remains an important component of cancer treatment with approximately 50.0% of all cancer patients receiving radiation therapy during their course of illness. The technological development in radiotherapy is mainly focused on improving therapy procedures and launching new products that have advanced features that help in the treatment of cancer patients.

Segmental Outlook

The global intensity modulated radiotherapy market is segmented on the radiation type, application, and end-users. Based on the radiation type, the market is sub-segmented into photon radiation, electron beam radiation, proton radiation, and carbon ion radiation. Based on the application, the market is sub-segmented into prostate cancer, breast cancer, lung cancer, gastrointestinal cancer, and other cancers. Further, based on end users, the market is sub-segmented into hospitals and specialty centers. Among the applications, the prostate cancer sub-segment is anticipated to hold a considerable share of the market as it most common type of external beam radiation therapy for prostate cancer. Many healthcare institutions are offering intensity modulated radiotherapy for prostate cancer such as Brigham and Women's Hospital, Blue Cross Hospitals, UCSF Health, and others.

The Photon Radiation Sub-Segment is Anticipated to Hold a Considerable Share of the Global Intensity Modulated Radiotherapy Market

Among the radiation types, the photon radiation sub-segment is expected to hold a considerable share of the global intensity modulated radiotherapy market. The segmental growth is attributed to the increasing use of photon beams in radiotherapy. Photons are also used in X-rays, but X-rays use lower doses. Photon beams can reach tumors deep in the body. As they travel through the body, photon beams scatter little bits of radiation along their path. In November 2021, Siemens Healthineers launched Naeotom Alpha, the first photon-counting CT scanner. The system is cleared for clinical use in the US and Europe. Conventional CT imaging has reached its technical limitations: Resolution can only be improved by small margins and dose cannot be reduced significantly: Photon-counting technology enables drastic improvements.

Regional Outlook

The global intensity modulated radiotherapy market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to an increase in demand for effective treatment options such as radiotherapy as more individuals are diagnosed with cancer.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Intensity Modulated Radiotherapy Market

Among all regions, the Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the growing adoption of modern and advanced technology-based radiotherapy procedures comprising the use of three-dimensional (3D) imaging technology, high-energy x-ray machines, and computerized treatment planning, that enhances the chances for more precise treatment possible. The increasing number of patients who successfully use radiation therapy owing to technological advancement in radiotherapy and novel technology in radiotherapy for cancer treatment is expected to drive market growth. According to the National Institute of Health (NIH), in June 2022, Global Cancer Statistics estimated, that Asia accounts for 59.5% of the global population. For both sexes combined, nearly 50.0% of all cancers and 58.3% of cancer-related deaths were estimated to occur in Asia in the year 2020. The estimated cancer incidence in Asia was 49.3% in 2020, compared with 22.8% in Europe and 20.9% in North and South America. China and India are expected to dominate in the Asia-Pacific region due to rising R&D activities and patient inclination towards personalized treatment. The rising prevalence of cancer and technological advancements are anticipated to enhance the market growth during the forecast period in this region.

Market Players Outlook

The major companies serving the intensity modulated radiotherapy market include Hitachi, Ltd., Koninklijke Philips N.V., Siemens Healthineers AG., Accuray, Inc., Hitachi, Ltd., Mevion Medical Systems., Sumitomo Heavy Industries, Ltd., and Varian Medical Systems, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2022, CERN, the Centre Hospitalier Universitaire Vaudois (CHUV), and THERYQ (ALCEN group) signed an agreement for the development of a revolutionary FLASH radiotherapy device that will use very high-energy electrons (VHEE) to treat cancers. Further, in October 2021, the Apollo Hospitals Group, Asia’s foremost integrated healthcare services provider, launched Varian’s TrueBeam radiotherapy system with Velocity, an intelligent software solution for interventional oncology at Apollo Cancer Institute. The versatile TrueBeam is capable of treating a wide range of cancers with high accuracy and precision allowing oncologists or cancer specialists to treat many types of complex cancer cases.

The Report Covers

Market value data analysis of 2022 and forecast to 2030.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global intensity modulated radiotherapy market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying ‘who-stands-where’ in the market.